Claim Missing Document
Check
Articles

Found 2 Documents
Search

The Correlation between Abdominal Circumference and Psoriasis Vulgaris Incidence Vrenda Alia; Muhammad Eko Irawanto; Laura Noviani; Ivani Ivani; Nurul Hidayati
Journal of Social Research Vol. 4 No. 7 (2025): Journal of Social Research
Publisher : International Journal Labs

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55324/josr.v4i7.2601

Abstract

Psoriasis is a chronic inflammatory skin condition that is often associated with various comorbidities, including cardiovascular disease, obesity, diabetes mellitus, and psoriatic arthritis. Obesity, particularly abdominal obesity, is known to impact the effectiveness of psoriasis treatment. This study aims to explore the relationship between abdominal circumference and the incidence of psoriasis in patients at the Dermatology and Venereology Polyclinic of Dr. Moewardi Hospital, Surakarta. The objective of this research was to determine whether abdominal circumference (waist circumference) is associated with the incidence of psoriasis in patients at the Dermatology and Venereology Polyclinic. A cross-sectional study was conducted with 30 psoriasis vulgaris patients treated at the clinic from July to August 2024. Waist circumference was categorized as high or normal. Data analysis was performed using the Mann-Whitney test and logistic regression analysis. The majority of participants (70%) had high waist circumference. Statistically, only age showed a significant relationship with psoriasis incidence (p = 0.015). Gender, BMI status, and waist circumference did not significantly correlate with psoriasis incidence (p = 0.069, p = 0.789, p = 0.284, respectively). This study suggests that waist circumference does not have a significant relationship with the incidence of psoriasis. Future research could explore other factors contributing to psoriasis exacerbation, such as metabolic syndrome or visceral adiposity.
Comparative Effect Of Topical Sucralfate Cream On Wound Size In Sprague–Dawley Rats With Second-Degree Burns Vrenda Alia; Triasari Oktavriana; Prasetyadi Mawardi; Muhammad Eko Irawanto; Arie Kusumawardani
Eduvest - Journal of Universal Studies Vol. 6 No. 7 (2026): Eduvest - Journal of Universal Studies
Publisher : Green Publisher Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59188/eduvest.v6i7.53025

Abstract

Background: Second-degree burns result in significant tissue damage and require optimal management to prevent complications and delayed healing. Silver sulfadiazine (SSD) is widely used as a standard topical therapy for burn wounds. Topical sucralfate has cytoprotective properties and has been suggested to enhance wound healing, making it a promising adjuvant therapy in wound management. Objective: To compare the reduction in second-degree burn wound size following treatment with 10% sucralfate cream, 7% sucralfate cream, and silver sulfadiazine in a rat model Methods: This experimental study employed a post-test only control group design using 48 Sprague Dawley rats with standardized second-degree burn injuries. The subjects were randomly allocated into four groups: Negative control with no treatment (NC), positive control with silver sulfadiazine (PC), treatment group with 7% sucralfate cream (T1), treatment group with 10% sucralfate cream (T2). Wound size was evaluated on days 1, 3, 7, and 14 using digital photographic analysis. Results: A statistically significant difference in wound size reduction was observed among the groups on day 14 (p < 0.001). The 10% sucralfate group (T2) demonstrated the greatest wound reduction, with a mean wound diameter of 44.62 ± 21.43 mm, which was comparable to the silver sulfadiazine group (48.89 ± 10.41 mm). Both groups showed significantly smaller wound sizes compared to the 7% sucralfate group (281.35 ± 99.33 mm) and the negative control group (936.48 ± 159.71 mm). Conclusion: The second-degree burn wound size in the 10% sucralfate group was smaller compared to the 7% sucralfate and silver sulfadiazine groups.